First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

被引：2
|
作者：
Rodler, E. T.
Infante, J. R.
Siu, L. L.
Smith, D. C.
Sullivan, D.
Vlahovic, G.
Gomez-Navarro, J.
Liu, G.
Blakemore, S.
Thompson, A.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3071
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [32] A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis
    Redman, Rebecca Ann
    Pohlmann, Paula Raffin
    Kurman, Michael R.
    Tapolsky, Gilles
    Chesney, Jason
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [33] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [34] Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.
    Richardson, Paul Gerard Guy
    Berdeja, Jesus G.
    Niesvizky, Ruben
    Lonial, Sagar
    Roy, Vivek
    Hari, Parameswaran
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
    Khot, Amit
    Brajanovski, Natalie
    Cameron, Donald P.
    Hein, Nadine
    Maclachlan, Kylee H.
    Sanij, Elaine
    Lim, John
    Soong, John
    Link, Emma
    Blombery, Piers
    Thompson, Ella R.
    Fellowes, Andrew
    Sheppard, Karen E.
    McArthur, Grant A.
    Pearson, Richard B.
    Hannan, Ross D.
    Poortinga, Gretchen
    Harrison, Simon J.
    [J]. CANCER DISCOVERY, 2019, 9 (08) : 1036 - 1049
  • [37] Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies
    Kurzrock, Razelle
    Wheler, Jennifer
    Hong, David S.
    Guo, Zhong
    Mulcahy, Mary F.
    Benson, Al B., III
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [38] Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
    Jones, S. F.
    Cohen, R. B.
    Bendell, J. C.
    Denlinger, C. S.
    Harvey, R. D.
    Parasuraman, S.
    Chi, X.
    Scholz, C.
    Wyant, T.
    Kauh, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    [J]. ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [40] Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study
    Guo, Z.
    Wheler, J. J.
    Naing, A.
    Mani, S.
    Goel, S.
    Mulcahy, M.
    Gamza, F.
    Longley, C.
    Buchbinder, A.
    Kurzrock, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345